252 related articles for article (PubMed ID: 27567889)
21. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.
Son BK; Kwak HW; Kim ES; Yu SY
Korean J Ophthalmol; 2017 Jun; 31(3):209-216. PubMed ID: 28471106
[TBL] [Abstract][Full Text] [Related]
22. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
23. Management of Choroidal Neovascular Membranes Associated with Choroidal Nevi.
Munie MT; Demirci H
Ophthalmol Retina; 2018 Jan; 2(1):53-58. PubMed ID: 31047303
[TBL] [Abstract][Full Text] [Related]
24. One-year outcomes of anti-vascular endothelial growth factor therapy in peripapillary choroidal neovascularisation.
Singh SR; Fung AT; Fraser-Bell S; Lupidi M; Mohan S; Gabrielle PH; Zur D; Iglicki M; M López-Corell P; Gallego-Pinazo R; Farinha C; Lima LH; Mansour AM; Casella AM; Wu L; Silva R; Uwaydat SH; Govindahari V; Arevalo JF; Chhablani J
Br J Ophthalmol; 2020 May; 104(5):678-683. PubMed ID: 31401554
[TBL] [Abstract][Full Text] [Related]
25. Baseline clinical features predict visual outcome in young patients with central retinal vein occlusion.
Koh YY; Lai CC; Wu WC; Hwang YS; Chen KJ; Wang NK; Chen TL; Huang JC; Liu L; Yeung L
Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1367-1377. PubMed ID: 32281001
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
Kim M; Jeong S; Sagong M
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
[TBL] [Abstract][Full Text] [Related]
27. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
28. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Choroidal Topographic Changes by Swept-Source Optical Coherence Tomography After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
Razavi S; Souied EH; Darvizeh F; Querques G
Am J Ophthalmol; 2015 Nov; 160(5):1006-13. PubMed ID: 26275471
[TBL] [Abstract][Full Text] [Related]
30. Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab.
Brogan K; Precup M; Rodger A; Young D; Gilmour DF
BMC Ophthalmol; 2018 Feb; 18(1):37. PubMed ID: 29426292
[TBL] [Abstract][Full Text] [Related]
31. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
32. Changes in choroidal structure following intravitreal aflibercept therapy for retinal vein occlusion.
Mitamura Y; Enkhmaa T; Sano H; Niki M; Murao F; Egawa M; Sonoda S; Sakamoto T
Br J Ophthalmol; 2021 May; 105(5):704-710. PubMed ID: 32620686
[TBL] [Abstract][Full Text] [Related]
33. Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections.
Osaka R; Muraoka Y; Miwa Y; Manabe K; Kobayashi M; Takasago Y; Ooto S; Murakami T; Suzuma K; Iida Y; Tsujikawa A
Ophthalmologica; 2018; 239(1):27-35. PubMed ID: 28946138
[TBL] [Abstract][Full Text] [Related]
34. INFLAMMATORY CHOROIDAL NEOVASCULAR MEMBRANE: Long-Term Visual and Anatomical Outcomes After Intravitreal Anti-vascular Endothelial Growth Factor Therapy.
Dʼsouza P; Ranjan R; Babu U; Kanakath AV; Saravanan VR
Retina; 2018 Jul; 38(7):1307-1315. PubMed ID: 28520642
[TBL] [Abstract][Full Text] [Related]
35. MACULAR CHOROIDAL VOLUME CHANGES AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Palkovits S; Seidel G; Pertl L; Malle EM; Hausberger S; Makk J; Singer C; Osterholt J; Herzog SA; Haas A; Weger M
Retina; 2017 Dec; 37(12):2262-2268. PubMed ID: 28129216
[TBL] [Abstract][Full Text] [Related]
36. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
[TBL] [Abstract][Full Text] [Related]
37. Choroidal volume in branch retinal vein occlusion before and after intravitreal anti-VEGF injection.
Chung YK; Shin JA; Park YH
Retina; 2015 Jun; 35(6):1234-9. PubMed ID: 25574783
[TBL] [Abstract][Full Text] [Related]
38. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
Brown DM; Wykoff CC; Wong TP; Mariani AF; Croft DE; Schuetzle KL;
Retina; 2014 Sep; 34(9):1728-35. PubMed ID: 24914476
[TBL] [Abstract][Full Text] [Related]
39. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
[TBL] [Abstract][Full Text] [Related]
40. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
